Causes of secondary and tertiary adrenal insufficiency in adults

INTRODUCTION

Adrenal insufficiency can be caused by diseases of the adrenal gland (primary), interference with corticotropin (ACTH) secretion by the pituitary gland (secondary), or interference with corticotropin-releasing hormone (CRH) secretion by the hypothalamus (tertiary). This topic will review the major causes of the latter two disorders; the causes of primary adrenal insufficiency, and the clinical manifestations and approach to diagnosis are discussed separately. (See "Causes of primary adrenal insufficiency (Addison's disease)" and "Clinical manifestations of adrenal insufficiency in adults" and "Diagnosis of adrenal insufficiency in adults".)

 

SECONDARY ADRENAL INSUFFICIENCY

Any process that involves the pituitary and interferes with ACTH secretion can cause secondary adrenal insufficiency. The ACTH deficiency may be isolated, or occur in conjunction with other pituitary hormone deficiencies (panhypopituitarism).

 

Panhypopituitarism — Pituitary tissue can be destroyed and hormone secretion reduced by large pituitary tumors or craniopharyngiomas, infectious diseases such as tuberculosis or histoplasmosis, infiltrative diseases, lymphocytic hypophysitis, head trauma, and large intracranial artery aneurysms. Pituitary infarction can occur at the time of delivery if excessive blood is lost and hypotension occurs (Sheehan's syndrome), and hemorrhage may occur into a pituitary tumor (pituitary apoplexy). Pituitary metastases are frequently (about 5 percent) found in patients with disseminated cancer at autopsy; however, these metastases rarely reduce hormone secretion [1]. (See "Causes of hypopituitarism".)

 

ACTH deficiency due to genetic pituitary abnormalities is rare. ACTH and cortisol deficiency have been described in patients with multiple pituitary hormone deficiencies due to mutations in the PROP-1 (Prophet of Pit-1) gene, even though PROP-1 is not expressed in corticotropes. The onset of cortisol deficiency, which may be severe, ranges from childhood to late adulthood [2-5]. Mutations in other transcription factors involved in early pituitary development (HESX1, LHX4) also can result in variable degrees of hypopituitarism that include ACTH deficiency [6,7]. (See "Causes of hypopituitarism".)

 

Isolated ACTH deficiency — Isolated ACTH deficiency is a rare disorder [8]. The defect is probably at the pituitary level because there is no ACTH secretory response to CRH or vasopressin, as there usually is in hypothalamic disorders [9-11]. Occasional patients may have hypothyroxinemia and hyperprolactinemia that are corrected with glucocorticoid replacement [12,13].

 

To continue reading this article you need to subscribe.

The Emerging Role of Robotics in Adrenal Surgery

The Emerging Role of Robotics in Adrenal Surgery

Journal
Current Urology Reports

Publisher
Current Medicine Group LLC

ISSN
1527-2737 (Print) 1534-6285 (Online)

DOI
10.1007/s11934-009-0079-7

Subject Group
Medicine

Accepted

PDF (133.6 KB) | HTML | Free Preview

Authors

James S. Rosoff¹ , Brandon J. Otto¹ , Joseph J. Del Pizzo¹

¹New York-Presbyterian Hospital Department of Urology, Weill Cornell Medical Center 525 East 68th Street, Starr 900 New York NY 10065 USA

Abstract

Abstract  Robotic surgery is being performed more frequently for a variety of urologic procedures. Since the first robotic adrenalectomy less than a decade ago, this modality has gained increased acceptance in the urologic community and has been employed with increased frequency in minimally invasive centers. This review evaluates the current literature on robotic adrenalectomy, its indications, as well as its advantages and limitations compared with other forms of surgical management of adrenal pathology.

Keywords

Adrenalectomy, Robotics, Minimally invasive

Fulltext Preview (Small, Large)

From http://www.metapress.com/content/kn5x5nr334561875/

Incidentally-discovered Adrenal Masses

Author: Milton D Gross

Specialty: Radiology, Nuclear Medicine, Endocrinology
Institution: Division of Nuclear Medicine, Department of Radiology, University of Michigan
City: Ann Arbor; State/Province: Michigan; Postal Code: 48105; Country: United States

Author: Melvyn Korobkin

Specialty: Radiology
Institution: Division of Abdominal Imaging, Department of Radiology, University of Michigan Medical Center
City: Ann Arbor; State/Province: Michigan; Country: United States

 

Author: Wessam Bou-Assaly

Specialty: Radiology
Institution: Department of Radiology, University of Michigan Medical Center
City: Ann Arbor; State/Province: Michigan; Country: United States
Institution: Radiology Service, Department of Veterans Affairs Health System
City: Ann Arbor; State/Province: Michigan; Country: United States

Author: Domenico Rubello

Specialty: Radiology
Institution: Department of Nuclear Medicine, PET Center, and Medical Physics and Radiology, Santa Maria della Misericordia Hospital
City: Rovigo; Country: Italy

 

Abstract: Unanticipated adrenal masses are frequently encountered in modern, high resolution diagnostic imaging. Most often, these masses are benign adrenal adenomas, but when detected they necessitate a clinical evaluation sufficient to exclude subclinical endocrine disease, primary adrenal cancer, and remote metastases to the adrenal glands from other malignancies. These "incidentally-discovered" adrenal masses or so-called "adrenal incidentalomas" can be further evaluated with CT, MRI, and nuclear medicine imaging techniques. A substantial literature supports the use of each of these modalities to non-invasively characterize these neoplasms that have been considered by some as a 'disease' by modern imaging technology.

 

Introduction

Over the last 3 decades the more widespread use of high-resolution CT and MRI have seen the frequent, “incidental” discovery of clinically unsuspected masses of the adrenal glands. Detection of these masses raises the specter of malignancy and forces further diagnostic evaluation to determine their etiology and to distinguish benign masses from those that would substantially change the clinical approach to the patient.

 

In patients undergoing CT for reasons other than adrenal disease, adrenal masses are incidentally discovered in 0.4-4.5% (Kloos et al., 1995). The majority of adrenal masses, ranging from 7% to 94%, are benign and hormonally non-functional, while in patients with malignancy the incidence of unsuspected adrenal masses ranges from 7% to 68% (Kloos et al., 1995). Metastases from other cancers to the adrenal occur in up to 20% of patients without previously diagnosed cancers and in almost 75 % of patients harboring non-adrenal primary malignancies (Kloos et al., 1995) (Table 1).

 

The incidence of clinically unsuspected adrenal masses increases with age greater than 30 years, regardless of gender. Clinically silent, hormonally active adrenal masses include tumors that produce hormones from all of the functional zones of the adrenal cortex and the adrenal medulla. As a result it is important that once discovered, and prior to any further imaging, a biochemical evaluation sufficient to exclude pheochromocytoma, normokalemic primary aldosteronism, and subclinical hypercortisolism be done as these conditions are optimally managed by surgical removal of the offending tumor (Young, 2007).

 

Methods of Adrenal Gland Imaging

Computed tomography is the most common imaging modality that identifies unsuspected adrenal masses in the evaluation of the chest and upper abdomen for diseases unrelated to the adrenal glands (Gross at al., 2005). Both CT and MRI can be used to differentiate normal from abnormal adrenal glands and MRI has been used to characterize incidentally discovered adrenal masses in clinical situations where CT is non-diagnostic (Gross et al., 2009) (Table 2).

 

Computed tomography and magnetic resonance imaging

 

Contemporary CT scanners using slice thicknesses of 3-5 mm will reliably depict the adrenal glands in virtually all patients. Comparison of non-contrast to contrast-enhanced CT can be used to distinguish adrenal masses and for evaluating retention and patterns of contrast washout as a means to differentiate adenomas from other adrenal neoplasms (Boland et al., 2008). MRI can be used to advantage in the evaluation of normal adrenal glands and adrenal masses. Gradient-echo, chemical shift MRI with in- and opposed-phrase imaging, and dynamic contrast-enhanced MRI detect lipid content in adrenal adenomas and, when combined with chemical shift ratios, depict the adrenal glands with an efficacy similar to CT (Dunnick et al., 2002). Hybrid scanners marrying CT, and perhaps in the near future MRI, with positron emission tomography (PET) and single photon emission tomography (SPECT) employing radiopharmaceuticals designed to target unique aspects of adrenal gland function(s) offer direct combination of anatomic and functional information that enhances diagnosis and differentiation of benign from malignant adrenal lesions (Gross et al., 2009).

 

Adrenal scintigraphy

The radiocholesterol analogs, ¹³¹I-6β-iodomethyl-19-norcholesterol (NP-59) and selenium-75-6β-iodomethyl-19-norcholesterol (Scintadren®) were some of the first successful radiopharmaceuticals used to image the adrenal cortex (Gross et al., 2007). Radiolabeled inhibitors of enzymes responsible for adrenal steroid hormone biosynthesis like the 11β-hydroxylase inhibitor, carbon-11-metomidate (¹¹C-MTO), can also be used to image neoplasms of adrenocortical origin. Other radiolabeled substrates depict metabolic processes such as the radio-fluorine-labeled ¹⁸F-fluorodeoxyglucose (FDG) to identify primary adrenal neoplasms and metastases to the adrenals, while ¹¹C-labeled acetate and ¹¹C- and ¹⁸F-labeled choline have been used to depict adrenal adenomas (Gross et al., 2007).

Radiolabeled metaiodobenzylguanidine (MIBG) has been used to identify the adrenal medulla and localize neoplasms of adrenomedullary origin by exploiting norepinephrine-re-uptake mechanisms into the catecholamine storage vesicles of adrenergic tissues.

 

Hydroxyephedrine, an analog of norepinephrine, can be labeled with ¹¹C or ¹⁸F, and is transported into adrenergic nerve terminals by these same mechanisms. The list of catecholamine-based PET radiopharmaceuticals used to image the adrenal medulla, related tissues, and tumors of sympathomedullary origin now includes ¹¹C-epinephrine, ¹¹C- or ¹⁸F-hydroxyepinephrine, ¹⁸F-fluorodopamine (FDA), and ¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-DOPA) (Shulkin et al., 2006). Alternatively, somatostatin receptor uptake of specific imaging agents can be used to image tissues that express somatostatin receptors, like the adrenal medulla and many other tissues and neoplasms. Octreotide, a long-acting somatostatin antagonist labeled with a variety of radioisotopes (¹¹¹Indium, ¹²³Iodine, ^99mTechnetium for SPECT, and ⁶⁸Gallium for PET imaging) can be used to accurately localize and stage primary and metastatic sympathomedullary tumors (Gross et al., 2007).

 

Imaging Incidentally-discovered Adrenal Masses

The differential diagnostic list of incidentally-discovered adrenal masses is long and a description of all but the most common is outside the scope of this short review. An extensive medical literature is available that describes the imaging characteristics of adrenal masses (Gross et al., 2005).

 

Adrenal adenoma

Adrenal adenomas are depicted on CT with density values expressed as Hounsfield units (HU) that are similar to normal adrenal tissues and depending upon their lipid content may express HU values similar to tissue water density (Korobkin et al., 1996). Furthermore, adenomas demonstrate increasing density, so-called “enhancement,” after intravenous CT contrast with more rapid loss of contrast — “washout” as compared to adrenal metastases (Korobkin et al., 1998). Like CT, MRI characteristics of adenomas are also similar to normal adrenal tissues. Signal intensity of adenomas is low on T2-weighted MR imaging sequences, but there is overlap (20-30%) with the signal intensity of metastases to the adrenal. Chemical-shift imaging is useful to depict tissue lipid content and is often employed to differentiate adenomas from metastases to the adrenal (Dunnick et al., 2002).

 

Pheochromocytoma

Pheochromocytomas are often clinically silent and present on high resolution anatomic imaging as incidentally-discovered adrenal masses. These neoplasms show enhancement with intravenous contrast agents in a fashion similar to malignant adrenal masses and occasionally may mimic contrast washout characteristics of benign adrenal adenomas. The imaging uncertainty posed by pheochromocytomas demands a biochemical evaluation sufficient to exclude catecholamine hypersecretion in suspect patients. Concerns over the potential of intravenous contrast-induction of hypertensive crisis have recently been allayed with nonionic contrast agents. Like CT, pheochromocytomas are usually hyperintense on T2-weighted imaging; however, there is overlap and about 30% are hypointense on T2-weighted imaging sequences (Blake et al., 2004).

 

Adrenal carcinoma

Adrenal carcinoma is a rare neoplasm (~ 2/10⁶ patients) that usually presents late in the course of disease. Adrenal carcinoma is often imaged as a large, heterogeneous abdominal mass with central necrosis, calcification, and tumor venous extension on contrast enhanced CT (Gross et al., 2009). On MRI these neoplasms are hyperintense on both T1- and T2-weighted imaging sequences from intra-tumor hemorrhage and central necrosis.

 

Adrenal metastases

Adrenal glands are common sites of remote metastases from cancers of the lung, breast, and melanoma. Adrenal metastases can be unilateral, bilateral, and variable in size. CT and MRI are nonspecific. Small metastases are often homogeneous on contrast CT or MRI, while large metastases are heterogeneous as a result of intra-metastasis necrosis and hemorrhage.

 

Distinguishing benign from malignant adrenal masses

Figure 1. An adrenal mass (arrow) is identified on CT (panel A) with characteristics of an adenoma with a non-contrast CT density (panel B) of 9.8 HU.

 

CT can be used to distinguish adrenal adenomas from metastases since most adenomas demonstrate non-contrast densities that are lower than metastases to the adrenal. The highest diagnostic efficacy for diagnosis of adrenal adenomas is obtained by selecting a threshold density value of 10 HU on non-contrast CT, as HU values for adenomas and adrenal hyperplasia are typically lower than those of metastases to the adrenal and pheochromocytomas (Figures 1 and 2).

 

Chemical-shift MRI also differentiates adrenal adenomas from metastases. By exploiting the different resonant frequencies of hydrogen in tissue water and lipid molecules, chemical-shift MRI detects a loss of signal intensity of tissues with high lipid and water content. Using gradient-echo imaging techniques, signal intensity loss on opposed-phase as compared to in-phase images differentiates tissues that contain lipids with high sensitivity and specificity. As lipids are common components of adrenal adenomas that are usually absent in metastases, this difference in lipid content can be exploited for the differentiation of adenomas vs. metastases to the adrenals (Figures 3 and 4).

Figure 2. Abdominal CT of bilateral adrenal masses (arrows) shows persistent enhancement of the right adrenal gland after intravenous contrast at 1.5 (panel B) and 5 min (panel C) after contrast injection in a pattern compatible with metastases to the adrenals.

 

In a combined histological CT and MRI study of adrenal adenomas there was an inverse relationship between lipid-containing cells and unenhanced CT, and a positive correlation with the relative change in signal intensity on opposed-phase MRI confirming that non-contrast CT and chemical-shift MRI might not necessarily complement each other in the evaluation of adrenal adenomas (Outwater et al., 1996). Contrast-enhanced CT images of the adrenals are obtained about 1 minute after a bolus intravenous injection of contrast and at this time point the attenuation values of adenomas and metastases are nearly identical (Figure 2B and Figure 5C). However, over time adenomas demonstrate loss of contrast enhancement and attenuation values on contrast enhanced CT of < 30-40 HU at 10-15 minutes post contrast injection can be used to distinguish, with few exceptions, adenomas from other adrenal masses (Gross el al., 2009).

 

Figure 3. MRI of a right adrenal nodule (arrows) demonstrates post-contrast enhancement on T1-weighted imaging (panel C) and displays loss of signal on out-of-phase (panel B) compared to in-phase imaging (panel A) confirming the mass as an adrenal adenoma.

 

Adrenal gland contrast washout as a percentage of initial enhancement is another parameter that can be used to identify adenomas from other adrenal masses. Adrenal adenomas have characteristic washout percentages of ~ 60% at 15 minutes post contrast administration corresponding to a sensitivity of 88% and a specificity of 96% for diagnosis of adenoma (Korobkin et al., 1998) (Figure 5). Further, so-called “lipid-poor” adenomas with unenhanced CT attenuation of >10 HU have contrast enhancement washout values that are nearly identical to those of lipid-rich adenomas confirming the value of differential washout as a means to identify adrenal adenomas from other adrenal masses (Caoili et al., 2000).

 

Distinguishing adrenal adenoma from carcinoma

Figure 4. MRI of a right adrenal mass demonstrates heterogeneous post-contrast enhancement (panel C) with no signal loss on out-of-phase imaging (panel B) vs. in-phase imaging (panel A) confirming the mass to be an adrenal metastasis.

 

Any adrenal mass larger than 5 to 6 cm in diameter is considered suspicious for an adrenocortical carcinoma. Large, non-secreting pheochromocytomas, adrenal carcinoma, or adrenal metastases may be indistinguishable by CT and MRI. Size criteria for resection of adrenal masses varies widely from 3.5 to 6 cm, and while there is controversy concerning the approach to smaller masses there is general agreement that masses > 6 cm, regardless of their imaging characteristics, should be removed.

 

Scintigraphy of adrenal masses

There are a host of scintigraphic imaging agents, with each targeting a unique characteristic of adrenal gland function that can be used to assess the etiology of incidentally-discovered adrenal masses. Adrenal adenomas can be depicted with iodocholesterol with positive and negative predictive values of 89% and 100%, respectively, and the lateralization of tracer uptake to one gland may be predictive of the development of future functional autonomy.

 

Metaiodbenzylguanidine images masses of adrenomedulla origin with positive and negative predictive values of 83% and 100%, respectively, while ¹⁸F-FDG separated benign from malignant adrenal lesions with 100% sensitivity and specificity (Maurea et al., 2001). As a result, if functional imaging is to be used to evaluate adrenal masses in patients with no history of cancer, radiocholesterol scintigraphy should be the first imaging procedure to identify the most common incidentally-discovered adrenal mass, a benign adrenal adenoma, followed by MIBG to identify clinically silent pheochromocytomas. Should MIBG be non-diagnostic, ¹⁸F-FDG is to be used to identify a potentially malignant adrenal mass or remote metastasis to the adrenal. Conversely, in patients with a prior history of cancer, ¹⁸F-FDG would be the most optimal first imaging study in the search for metastatic disease to the adrenal followed in sequence by iodocholesterol and MIBG.

Figure 5. A left adrenal gland mass (arrow) with a density of 1.5 HU on non-contrast CT (panels A and B) increases after intravenous contrast administration to 50 HU on early post-contrast enhanced images (panel C), and falls to 4 HU on the delayed images (panel D). The calculated washout of 95% is compatible with a lipid rich, adrenal adenoma.

 

¹⁸F-FDG-PET can differentiate benign from malignant adrenal lesions and metastases to the adrenal (Figure 6). In a study of 150 patients with adrenal masses, ¹⁸F-FDG-PET had a sensitivity of 98.5% and a specificity of 92% at a standardized uptake value (SUV) threshold of 3.1 and with the addition of CT to FDG-PET specificity increased to 98% with all masses correctly characterized as benign or malignant (Metser et al., 2006). While in 50 patients with known or suspected malignancy, ¹⁸F-FDG-PET had a sensitivity of 100%, a specificity of 94%, and an accuracy of 96%, and by using the liver as a ‘normal’ comparison tissue it improved the sensitivity of ¹⁸F-FDG for detecting malignant adrenal lesions without sacrificing sensitivity (Yun et al., 2001). More recently ¹⁸F-FDG-PET was shown in a prospective multicenter trial to accurately differentiate adrenocortical adenomas from adrenal carcinomas and in particular a subgroup of masses with indeterminate findings on CT (Groussain et al., 2009).

 

In comparative studies of the 11β-hydroxylase inhibitor, ¹¹C-MTO, and ¹⁸F-FDG in incidentally-discovered masses, ¹¹C-MTO identified lesions of adrenocortical origin with the highest SUV in adrenocortical carcinoma, followed by hypersecretory adrenal cortical adenomas and non-hypersecretory adenomas, although ¹¹C-MTO-PET did not distinguish benign adrenocortical neoplasms from adrenocortical carcinoma (Hennings et al., 2006). ¹⁸F-FDG can be also used to image pheochromocytomas and adrenocortical carcinoma and to differentiate these neoplasms from other non-hypersecreting and most hypersecreting adrenal adenomas.

Figure 6. PET/CT scans of adrenal masses (white arrows). An ¹⁸F-FDG scan (panel A) shows no appreciable tracer accumulation in a left adrenal mass seen on CT (panel B) compatible with an adrenal adenoma. An adrenal metastasis from lung cancer (black arrows) is depicted on an ¹⁸F-FDG scan (panel C) as an intense focus of tracer uptake in a small left adrenal mass on CT (panel D).

 

Pheochromocytomas can be reliably imaged with ¹²³I- or ¹³¹I-MIBG with PET/CT using ¹⁸F-dopamine or ¹⁸F-DOPA (Shulkin et al., 2006) (Figure 7). In a comparison of the efficacy of ¹⁸F-FDA, ¹²³I-MIBG, and ¹¹¹In-octreotide, ¹⁸F-FDA demonstrated the highest sensitivity in the localization of intra-adrenal and metastatic pheochromocytomas, followed by ¹²³I-MIBG and ¹¹¹In-octreotide for intra-adrenal pheochromocytoma, while the efficacy of ¹⁸F-FDA and ¹²³I-MIBG were equivalent (Ilias et al., 2008). If catecholamine analogs are not successful in imaging, the neoplasm may have experienced malignant dedifferentiation, and ¹⁸F-FDG or ¹¹¹In-octreotide can be used to localize metastases and guide subsequent therapy.

 

Summary

Incidentally-discovered adrenal masses are commonly encountered in modern high-resolution imaging. The list of differential diagnostic possibilities of incidentally-discovered adrenal masses is large, but fortunately, most are benign and non-hyperfunctioning adenomas. The first consideration in the evaluation of an incidentally-discovered adrenal mass is its functional status and should include a biochemical evaluation sufficient to exclude clinically-silent endocrine disease. CT, MRI, and scintigraphy can be used to characterize incidentally-discovered adrenal masses and distinguish adrenal adenomas from metastases to the adrenals and other adrenal neoplasms. An understanding of the imaging techniques used to distinguish benign from malignant and other incidentally-discovered adrenal masses speeds diagnosis, optimizes therapy, and decreases costs in the evaluation of these neoplasms.

Figure 7. A small, left adrenal mass (arrow) on CT (panel A) demonstrates intense ¹⁸F-DOPA uptake (panel B) in a patient with hypertension and a prior negative ¹²³I-MIBG scan who was later shown to have elevated catecholamines compatible with a pheochromocytoma.

 

References

Blake MA. Kalra MK. Maher MM. Sahani DV. Sweeney AT. Mueller PR. Hahn PF. Boland GW. Pheochromocytoma: an imaging chameleon. Radiographics 24(Suppl 1):S87-99, 2004.

Boland GW. Blake MA. Hahn PF. Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 249(3):756-75, 2008.

Caoili EM. Korobkin M. Francis IR. Cohan RH. Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. Am J Roentgenol 175(5):1411-5, 2000.

Dunnick NR and Korobkin M. Imaging of adrenal incidentalomas: current status. Am J Roentgenol 179(3):559-68, 2002.

Gross MD, Korobkin M, Hussain H, Cho KJ, Bui C. “Adrenal Gland Imaging” Chapter 126. Endocrinology, 5^th Edition. JL. Jameson and LJ. Degroot, Eds. W.B. Saunders, Philadelphia, USA, pp. 2425-2453, 2005.

Gross MD, Avram A, Fig LM, Rubello D. Contemporary adrenal scintigraphy. European J Nucl Med Mol Imaging 34:547-57, 2007.

Gross MD, Korobkin M, Bou Assaly W, Dwamena B, Djekidel M. Contemporary imaging of incidentally discovered adrenal masses. Nat Rev Urol 6:363-73, 2009.

Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, et al. ¹⁸F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 94(5):1713-22, 2009.

Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. [¹¹C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91(4):1410-4, 2006.

Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, Adams KT, Perera S, Pacak K. Comparison of 6-¹⁸F-fluorodopamine PET with ¹²³I metaiodobenzylguanidine and ¹¹¹in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49(10):1613-9, 2008.

Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 16(4):460-84, 1995.

Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol 170(3):747-52, 1998.

Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP, Wang HH. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 200(3):743-7, 1996.

Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 42(6):884-92, 2001.

Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. ¹⁸F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 47(1):32-7, 2006.

Outwater EK, Siegelman ES, Huang AB, Birnbaum BA. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 200(3):749-52, 1996.

Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073:374-82, 2006.

Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42(12):1795-9, 2001.

[Discovery Medicine, Volume 9, Number 44, January 2010. Pre-published.]

Related Articles

• Dec 11, 2009 Magnetic Resonance Imaging of Brain Tumors - Time to Quantify
• May 23, 2009 In Vivo Imaging Tools Push Frontiers of Medical Discoveries
• Jul 17, 2009 Memory Dysfunction in Clinical Practice
• Jul 12, 2009 Positron Emission Tomography (PET) and Anticancer Drug Development
• Jun 19, 2009 Neurobiology of Intelligence: Health Implications?
• May 29, 2009 Increase of Signal-to-noise of More Than 10,000 Times in Liquid State NMR
• May 23, 2009 Scientists in the News: Drs. Lauterbur and Mansfield Won Nobel Prize in Physiology or Medicine
• Jan 08, 2010 Colon Capsule Endoscopy: A New Tool for Colon Examination?
• Jul 29, 2009 Magnetic Nanoparticles: Prospects in Cancer Imaging and Therapy
• Jul 25, 2009 Acute Stroke Management

From http://www.discoverymedicine.com/Milton-D-Gross/2010/01/04/incidentally-discovered-adrenal-masses/

Laparoscopic management of adrenal lesions larger than 5 cm in diameter - Abstract

Monday, 11 January 2010

Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India.

Laparoscopic adrenalectomy remains a controversial procedure for large tumors. The incidence of adrenocortical carcinoma increases and technical difficulty of adrenalectomy increases as the size increases. We examined the outcome and complications of laparoscopic adrenalectomy for such lesions.

 

Twenty-nine patients underwent laparoscopic adrenalectomy, of whom 19 had tumors larger than 5 cm in diameter, having a median tumor size of 7.0 cm. They were compared with patients whose adrenal tumors were smaller than 5 cm.

 

Patients with small tumors (< 5 cm) had a significantly shorter median operative time of 90 minutes as compared to 145 minutes in those with large tumors (> 5 cm). There was no significant difference in the median hemoglobin drop (1.05 g/dL versus 1.30 g/dL), time for starting oral intake (24 hours in both groups) or hospital stay (3.5 days versus 4.0 days) between patients with small and large tumors, respectively. There were no intra-operative complications except for 1 incidence of supraventricular tachycardia in a patient with a large pheochromocytoma. There were no major complications seen in any of the patients and no open conversions. Histopathology of large tumors revealed 16 benign tumors (8 pheochromocytomas, 4 adenomas, 2 ganglioneuromas, 1 pseudocyst, and 1 myelolipoma) and 3 malignancies, of which 1 was primary adrenocortical carcinoma and 2 were metastatic renal cell carcinoma.

 

In experienced hands, laparoscopic adrenalectomy is safe and feasible for large functioning adrenal tumors. Large adrenal tumors suspicious of harboring malignancy with no peri-adrenal involvement can be tackled laparoscopically.

 

Written by:
Sharma R, Ganpule A, Veeramani M, Sabnis RB, Desai M.   Are you the author?

 

Reference:
Urol J. 2009 Fall;6(4):254-9.

PubMed Abstract
PMID:20027553

UroToday.com Adrenal and Retroperitoneum Section

 

From http://www.urotoday.com/57/browse_categories/adrenal_and_retroperitoneum/laparoscopic_management_
of_adrenal_lesions_larger_than_5_cm_in_diameter__abstract01112010.html

Trying something new…again

I saw this on another site and I stayed up all night making one for Cushies because I thought it was so cool.

 

This is a toolbar you can install on any browser and it will link to what I think are the most important parts of the Cushing’s websites. If you have other ideas, please let me know.

Right now, this contains (from left to right)

1. The Cushie ribbon icon which takes you to the home page of the newer cushie.info site. Click on the little down arrow to the right of the ribbon and another whole menu appears!
   
   
2. Next to that is a Google search box.
3. An icon for the 911 Adrenal Crisis! page
4. A link to the Cushie Reads book recommendations page on amazon.com
5. The Cushie Calendar
6. All the bios, arranged by diagnosis type
7. Add (or update) your bio
8. Our locations around the world
9. The message boards and chatroom
10. Helpful Doctors list
11. Add (or update) your Helpful Doctor
12. The Support page where people can make donations to help keep all these websites going.
13. A little scrolling message area for Cushing’s news.
14. Cushing’s blogs. I’m still working on this – and I’m not sure how many I can add but for the moment, this blog is included as well as Cushie Bloggers and survive the journey
    
    When any of these update, the icon changes to show that there are new posts.
    
    This area now includes NIH Clinical trials for Cushing’s, pituitary and adrenal. Be the first to know when new trials are listed.
15. The Cushings Help Organization cause on Facebook
16. Links to Staticnrg and Cushings on Twitter. Again, more can be added. If you talk mostly about Cushing’s on Twitter, please let me know.
17. The new CushieWiki. BTW, please feel free to sign up and become a contributor/editor.
18. A radio button – you can play the Cushing’s podcasts right from this toolbar. You can also add stations that you’d like to listen to.
19. You can also add other modules like games, weather, email, hundreds of different things.

Download this toolbar or see a sample.

---

About privacy:

cushie tools is committed to maintaining the following privacy practices:

1. No Spyware Policy – the toolbar does not collect or transmits Identifiable information and does not monitor personal toolbar usage.
   The toolbar sends unidentifiable and non-personal statistical data to enable quality assurance and improve support processes. Such non-personal data includes unidentifiable usage of toolbar components and queries. You can opt not to send such statistical data at any time from your toolbar Options dialog box.
2. No Adware Policy : exposure to unwanted advertisements is not required in order to use the toolbar. The toolbar does not launch pop-up or pop-under advertisement windows or any other type of obtrusive ads.
3. Unobtrusive: The toolbar does not enable other applications to access data stored on your computer's hard drive or in your online accounts. The toolbar does not modify pages you visit or modify your search experience. You may voluntarily opt to receive Publisher notifications (such as Community Alerts) or use other advanced functionalities offered by cushie tools.
4. Easy uninstall : you can easily uninstall the toolbar at any time using the toolbar's standard uninstall package (Add/Remove Programs in Windows, Add-on Removal in Firefox, etc.).
5. Easy deactivation: you can easily deactivate your toolbar at any time by clicking the "View" menu in your browser and deselecting the name of your community toolbar.
6. Full control : you have full control over your toolbar and you can add/remove toolbar components at any time using your toolbar's Options dialog box.

7. Report - cushie tools is committed to ensuring your Privacy and safety while using your community toolbar. If you have a reason to believe that your rights have been infringed upon, please email privacy@conduit.com to contact the owners of Platform that was used by cushie tools to create your community toolbar, and your application will be handled at the earliest convenience.

Finally, I would like to add that installing this toolbar is possibly a way for the sites to make a little money although the hosting site doesn’t disclose how much they give back and how many people have to do how much searching to make any kind of profit.

 

The theory is that Google pays the host company, Conduit, like it does for Google ads – I’ve seen them on other sites but have never used them because I want to try to keep the sites ad free and non-tacky. Then, depending on the number of people who have installed this toolbar, and how much they use it, a percentage of that money is supposed to come back to Cushing’s Help.

 

I have no expectations of making any money, though. I just thought that it looked like an interesting new way for people to find things easily on the websites, listen to podcasts, and get the latest news.

 

Please note – after installation there’s a little popup window that says you might get alerts. I promise I won’t send those out unless it’s something serious like the boards are back up after a day of being down.

 

Thanks for reading! I hope you’ll give this a try.

Addison's Blog Alerts

Training because I can! Addison's disease, exercise and living in ...
By Dusty
Training because I can! Addison's disease, exercise and living in Idaho. Image Hosted by ImageShack.us ... Addison's Support, there's more than just this blog. Addison's Support the links · Addison's Support the Forum ...
Training because I can! Addison's... - http://addisonssupport.blogspot.com/

 

 

Addison Disease - Professional Medical Resources
Profession medical resources for "Addison Disease" including "Addison Disease: eMedicine Endocrinology", "Addison Disease: eMedicine Dermatology", ...

Addison Disease: eMedicine Endocrinology

is more than 2-fold higher in patients with Addison disease. Cardiovascular malignant and infectious diseases are responsible for the higher mortality rate. ... is seen in association with hyperpigmentation in idiopathic autoimmune Addison disease. It is due to the autoimmune destruction of melanocytes. ... http://emedicine.medscape.com/article/116467-overview

 

Addison Disease: eMedicine Dermatology

Addison disease in developing countries. Currently in developed countries Addison disease most commonly results from nonspecific autoimmune destruction of the adrenal gland. ... Addison disease Addison's disease primary adrenal insufficiency chronic adrenal insufficiency hypoadrenalism polyglandular autoimmune diseases polyglandular autoimmune disease I PGAD I polyglandular autoimmune ... http://emedicine.medscape.com/article/1096911-overview